Document is current
Any future updates will be listed below
-
Authors
Ramachandran, Abhinay
Livingston, Carissa E.
Vite, Alexia
Corbin, Elise A.
Bennett, Alexander I.
Turner, Kevin T.
Lee, Benjamin W.
Lam, Chi Keung
Wu, Joseph C.
Margulies, Kenneth B. https://orcid.org/0000-0002-8093-4465
-
Funding
Funding for this research was provided by:
National Center for Advancing Translational Sciences (TL1TR001880)
Sidney Pestka M’61 Term Fellowship
National Institutes of Health (T32-HL007843)
American Heart Association (19CDA34770040)
National Heart, Lung, and Blood Institute (R01 HL126527, R01 HL130020, R01-HL149891)
National Center for Science and Engineering Statistics (CMMI: 15-48571)
Provost Postdoctoral Fellowship
Fondation Leducq (TNE ID#673168)
Gordon and Llura Gund Family Fund
- License Information
-
More Information
Article History
Received: 8 August 2022
Accepted: 17 December 2022
First Online: 6 March 2023
Declarations
:
: While no human studies were carried out by the authors for this article, we utilized two cell lines of Hu-iPSC-CMs from the Stanford Cardiovascular Institute that were employed in the previous studies []. As described in Seeger et al., the protocol for induced pluripotent stem cell generation and cardiomyocyte differentiation were in accordance with the ethical standards of and approved by the Stanford Institutional Review Board (IRB) and Stem Cell Research Oversight (SCRO) Committee, and with the Helsinki Declaration of 1975, as revised in 2000. iPSC lines were obtained from patients with informed consent []. All procedures are followed of the responsible committee on human experimentation (institutional and national). Informed consent was obtained from all patients included in the study. No animal studies were carried out.
: Dr. Kenneth Margulies receives consulting fees for serving on the advisory board for Bristol-Myers-Squibb (myosin inhibitors).
